



PATENT  
Attorney Docket No. 12971US04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Grant L. Schoenhard )  
Serial No.: 10/000,113 )  
Filing Date: October 30, 2001 )  
For: Inhibitors of ABC Drug Transporters at )  
the Blood-Brain Barrier )  
Examiner: Vickie Y. Kim )  
Group Art Unit No.: 1618 )  
Confirmation No.: 8969 )  
Customer No.: 23446 )

EXPRESS MAIL NO. EV 639809373 US

DATE OF MAILING: August 8, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement ("IDS") is being submitted with a Request for Continued Examination. In compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, this IDS, the attached Form PTO/SB/08A, and a copy of the document cited therein is submitted for consideration in connection with the above-identified patent application. It is respectfully requested that the Examiner indicate on attached Form PTO/SB/08A that the cited document has been considered.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present

patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Please charge any fees incurred in connection with this submission to Deposit Account No. 13-0017 in the name of McAndrews, Held & Malloy, Ltd.


Respectfully submitted,

Dated: August 8, 2005

A handwritten signature in cursive script, reading "Michael B. Harlin". The signature is written in dark ink and is positioned above a horizontal line.

Michael B. Harlin  
Registration No. 43,658  
Attorney for Applicant

McANDREWS, HELD & MALLOY, LTD.  
500 West Madison Street, 34th Floor  
Chicago, Illinois 60661  
Telephone: (312) 775-8000  
Facsimile: (312) 775-8100



PTO/SB/08A (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/000,113
Filing Date	October 30, 2001
First Named Inventor	Grant L. Schoenhard
Group Art Unit	1618
Examiner Name	Vickie Y. Kim
Attorney Docket Number	12971US04

**U.S. PATENT DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1				
	A2				
	A3				
	A4				
	A5				
	A6				
	A7				
	A8				
	A9				
	A10				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A11					
	A12					
	A13					
	A14					
	A15					

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	A16	Boström, Emma, et al., "Oxycodone Pharmacokinetics and Pharmacodynamics in the Rat in the Presence of the P-Glycoprotein Inhibitor PSC833," Journal of Pharmaceutical Sciences, Vol. 94, No. 5, May 2005 (1060-66).
	A17	
	A18	
	A19	
	A20	

EXAMINER SIGNATURE	DATE CONSIDERED
-----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

Rev. Sept. 03

X:\OPENUMM\Pain Therapeutics (1587)\PTO\12971\12971US04\12971US04-SB08A-08AUG05.doc